Panel of antibodies used in this study.

<p>Panel of antibodies used in this study.</p

Kaplan-Meier survival analysis revealed that the expression of cyclin D1was predictive for overall survival (OS) but not disease-free survival (DFS).

<p><i>CCND1</i> amplification was predictive for DFS. High cyclin D1 expression affected DFS in Luminal A cases.</p

Patients’ characteristics (n = 179).

<p>Patients’ characteristics (n = 179).</p

Univariate Cox regression analysis for clinicopathological factors.

<p>Univariate Cox regression analysis for clinicopathological factors.</p

Cyclin D1 expression and <i>CCND1</i> amplification in breast cancer subtypes.

<p>Cyclin D1 expression and <i>CCND1</i> amplification in breast cancer subtypes.</p

Cox multivariate analysis for prognostic factors.

<p>Cox multivariate analysis for prognostic factors.</p

Organometallic Glutathione <i>S</i>‑Transferase Inhibitors

A new family of organometallic <i>p</i>-cymene ruthenium­(II) and osmium­(II) complexes conjugated to ethacrynic acid, a glutathione transferase (GST) inhibitor, is reported. The ethacrynic acid moiety (either one or two) is tethered to the arene ruthenium­(II) and osmium­(II) fragments via strongly coordinating modified bipyridine ligands. The solid-state structure of one of the complexes, i.e. [Os­(η⁶-<i>p</i>-cymene)­Cl]­[(4′-methyl-[2,2′-bipyridin]-4-yl)­methyl-2-(2,3-dichloro-4-(2-methylenebutanoyl)­phenoxy)­acetate]­Cl, was established by single-crystal X-ray diffraction, corroborating the expected structure. The complexes are efficient inhibitors of GST P1-1, an enzyme expressed in cancer cells and implicated in drug resistance, and are cytotoxic to the GST-overexpressing chemoresistant A2780cisR ovarian cancer cell line